Search
(1R,2S)-2-Phenylcyclopropanaminium
go.drugbank.com/drugs/DB02665ExperimentalThis monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. … A propylamine formed from the cyclization of the side chain of amphetamine.
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906 … )[L12675] with an expected completion in December 2020.
Alrizomadlin
go.drugbank.com/drugs/DB17549InvestigationalAlrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.[A257281,A257286]
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalNCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants). … AZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.
Distigmine
go.drugbank.com/drugs/DB13694InvestigationalDistigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to [DB00545] and [DB01400].
Sovleplenib
go.drugbank.com/drugs/DB17557InvestigationalIt is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia). … Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk).
Refanezumab
go.drugbank.com/drugs/DB14908InvestigationalRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
Furvina
go.drugbank.com/drugs/DB16547ExperimentalFurvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063] … Furvina (G1) is an antimicrobial agent active against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi.
Nisoxetine
go.drugbank.com/drugs/DB09186ExperimentalNisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. … It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI.